Table 3.

Results of Kaplan–Meier analysis of clinical and PET-derived parameters.

	No. of Patients	Overall Survival (months), Mean (95% CI)	p
Gleason score
8–9	14	11.1 (7.5–14.7)	0.34
6–7	6	16.5 (13.4–19.5)
Previous CHT
No	16	13.8 (10.5–17.1)	0.09
Yes	4	8.5 (5.9–11)
Hb levels
≤12 g/L	6	9.5 (7.4–11.5)	0.1
>12 g/L	14	14.1 (10.3–17.9)
Number of lesions
≤20	15	14.4 (11–17.7)	0.01 *
>20	5	7.8 (5.9–9.7
ALP levels
≤150 U/L	18	13.3 (10.3–16.3)	0.1
>150 U/L	2	7.5 (4.5–10.4)
PSA levels
≤50.2 ng/mL	9	16.3 (11.3–21.3)	0.04 *
>50.2 ng/mL	11	9.8 (7.7–11.8)
SUVmax
≤13.8	10	14.3 (10.3–18.2)	0.3
>13.8	10	11.2 (7.1–15.2)
SUVmean
≤7	10	14.3 (10.3–18.2)	0.3
>7	10	11.2 (7.1–15.2)
SULpeak
≤8.4	12	13.9 (10.1–17.6)	0.3
>8.4	8	11 (6.6–15.3)
MATV
≤48.2 (cc)	9	16 (12.2–19.7)	0.1
>48.2 (cc)	11	10 (6.5–13.6)
TLA
≤351.5 (g)	10	17.1 (13.1–21)	0.003 *
>351.5 (g)	10	8.4 (7–9.7)

* p was significant at statistical analysis.